EUVIMEDEUVIMED entdecken
Crossref

Patient-Derived Organoids on a Microarray for Drug Resistance Study in Breast Cancer

Tianyuan Fang, Xinlun Xie, Wei Lu, Zichen Hong, Wenbo Peng, Jun Zhou, Min Wang, Bo Yao iD

Analytical Chemistry · 19.11.2024 · 96 (46) · 18384-18391

DOI: 10.1021/acs.analchem.4c02691 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Analytical Chemistry, online erschienen am 05.11.2024. Verfasst von Tianyuan Fang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Zhejiang University, Hangzhou 310058, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Drug Resistance, Neoplasm, Organoids, Doxorubicin. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Drug resistance is always a challenge in cancer treatment, whether for chemotherapy, targeting, or immunotherapy. Although tumor cell lines are derived from cancer patients, they gradually lost the original characteristics, including heterogeneity and tumor microenvironment (TME), during the long period of in vitro culturing. Therefore, it is urgent to use patient-derived tumor models instead of cancer cell lines to study tumor drug resistance. Herein, we developed a microarray device that serves as a platform for high-throughput and three-dimensional culture of breast cancer patient-derived organoids (BCOs) and investigated their resistance to adriamycin (ADM). Coupled with fluorescence microscopy, this system enabled on-chip drug response monitoring and cell viability assessment without the consumption of a large number of tumor cells. The organoids were divided into a resistant BCO group (RBCO) and a sensitive BCO group (SBCO) according to their half-inhibitory concentration (IC50). Different from cancer cell lines, BCOs demonstrated obvious heterogeneity in drug treatment. Ivermectin (IVM), a broad-spectrum antiparasitic agent approved by the Food and Drug Administration (FDA), was observed to synergistically augment ADM-induced cytotoxicity in organoids. The BCO chip provides a promising platform for investigation of drug resistance and preclinical drug screening based on clinical samples.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsDrug Resistance, NeoplasmOrganoidsDoxorubicinHumansFemaleCell SurvivalIvermectinDrug Screening Assays, AntitumorCell Line, TumorAntineoplastic AgentsTumor Cells, Cultured

Substanzen

DoxorubicinIvermectinAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Chemistry, Zhejiang University, Hangzhou 310058, China.
  • GeneX (Zhejiang) Precision Medicine Co., Ltd, Hangzhou 311100, China.
  • Department of Breast surgery, The First People's Hospital of Lianyungang, Lianyungang 222002, China.

ORCID-Profile: Bo Yao

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Fang, T., Xie, X., Lu, W., Hong, Z., Peng, W., Zhou, J., Wang, M., & Yao, B. (2024). Patient-Derived Organoids on a Microarray for Drug Resistance Study in Breast Cancer. Analytical Chemistry, 96(46), 18384-18391. https://doi.org/10.1021/acs.analchem.4c02691

Vancouver

Fang T, Xie X, Lu W, Hong Z, Peng W, Zhou J, et al. Patient-Derived Organoids on a Microarray for Drug Resistance Study in Breast Cancer. Analytical Chemistry. 2024;96(46):18384-18391. doi:10.1021/acs.analchem.4c02691

BibTeX
@article{Fang2024,
  author = {Fang, Tianyuan and Xie, Xinlun and Lu, Wei and Hong, Zichen and Peng, Wenbo and Zhou, Jun and Wang, Min and Yao, Bo},
  title = {Patient-Derived Organoids on a Microarray for Drug Resistance Study in Breast Cancer},
  journal = {Analytical Chemistry},
  year = {2024},
  volume = {96},
  number = {46},
  pages = {18384--18391},
  doi = {10.1021/acs.analchem.4c02691}
}
Kostenlos starten →